Reconstructed stem cell nanoghosts: a natural tumor targeting platform

Nano Lett. 2013 Jul 10;13(7):3248-55. doi: 10.1021/nl401376w. Epub 2013 Jun 24.

Abstract

The ultimate goal in cancer therapy is achieving selective targeting of cancer cells. We report a novel delivery platform, based on nanoghosts (NGs) produced from the membranes of mesenchymal stem cells (MSCs). Encompassing MSC surface molecules, the MSC-NGs retained MSC-specific in vitro and in vivo tumor targeting capabilities and were cleared from blood-filtering organs. MSC-NGs were found to be biocompatible. Systemic administration of drug loaded MSC-NGs demonstrated 80% inhibition of human prostate cancer.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antineoplastic Agents / administration & dosage
  • Antineoplastic Agents / pharmacokinetics
  • Cell Line, Tumor
  • Cell Membrane / chemistry*
  • Male
  • Mesenchymal Stem Cells / chemistry*
  • Mice
  • Mice, Inbred C57BL
  • Mice, Nude
  • Nanocapsules / administration & dosage
  • Nanocapsules / chemistry*
  • Nanocapsules / ultrastructure
  • Organ Specificity
  • Particle Size
  • Peptide Fragments / administration & dosage*
  • Peptide Fragments / pharmacokinetics*
  • Prostatic Neoplasms / drug therapy*
  • Prostatic Neoplasms / metabolism*
  • Receptors, TNF-Related Apoptosis-Inducing Ligand / administration & dosage*
  • Receptors, TNF-Related Apoptosis-Inducing Ligand / pharmacokinetics*
  • Tissue Distribution
  • Treatment Outcome

Substances

  • Antineoplastic Agents
  • Nanocapsules
  • Peptide Fragments
  • Receptors, TNF-Related Apoptosis-Inducing Ligand
  • soluble tumor necrosis factor-related apoptosis-inducing ligand (114-281), rat